{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:24:21Z","timestamp":1787775861484,"version":"build-2784847793"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11926-018-0792-7","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:13:59Z","timestamp":1541636039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?"],"prefix":"10.1007","volume":"20","author":[{"given":"S. A.","family":"Kerrigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"792_CR1","unstructured":"Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nature Publishing Group; 2015;12(1):25\u201336."},{"key":"792_CR2","doi-asserted-by":"crossref","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Publishing Group; 2017;17(1):843\u201362.","DOI":"10.1038\/nrd.2017.201"},{"key":"792_CR3","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. Elsevier Ltd; 2017;390(10093):457\u201368."},{"issue":"6","key":"792_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507.","journal-title":"N Engl J Med"},{"key":"792_CR5","doi-asserted-by":"crossref","unstructured":"Vieira M-C, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors_ results from a network meta-analysis. Clin Ther. Elsevier HS Journals, Inc; 2016;38(12):2628\u20132641.e5.","DOI":"10.1016\/j.clinthera.2016.11.004"},{"key":"792_CR6","doi-asserted-by":"crossref","unstructured":"Eisenstein EM, Berkun Y. Diagnosis and classification of juvenile idiopathic arthritis. J Autoimmun. Elsevier Ltd; 2014;48-49(c):31\u20133.","DOI":"10.1016\/j.jaut.2014.01.009"},{"key":"792_CR7","doi-asserted-by":"crossref","unstructured":"Giancane G, Consolaro A, Lanni S, Dav\u00ec S, Schiappapietra B, Ravelli A. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3(2):187\u2013207.","DOI":"10.1007\/s40744-016-0040-4"},{"issue":"12","key":"792_CR8","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez J-B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023\u201338.","journal-title":"J Med Chem"},{"key":"792_CR9","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. Springer International Publishing; 2017;77(5):521\u201346."},{"key":"792_CR10","unstructured":"Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant. Wiley\/Blackwell (10.1111); 2004;4(1):51\u20137."},{"issue":"6","key":"792_CR11","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/art.37913","volume":"65","author":"S Prahalad","year":"2013","unstructured":"\u2022 Prahalad S, Conneely KN, Jiang Y, Sudman M, Wallace CA, Brown MR, et al. Brief report: susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci. Arthritis Rheum. 2013;65(6):1663\u20137 This study nicely illustrates the genetic similarities between rheumatoid arthritis and RF+ve JIA.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"792_CR12","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/art.24601","volume":"60","author":"MG Barnes","year":"2009","unstructured":"Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(7):2102\u201312.","journal-title":"Arthritis Rheum"},{"key":"792_CR13","unstructured":"Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. Wiley-Blackwell; 2005;52(3):826\u201332."},{"key":"792_CR14","doi-asserted-by":"crossref","unstructured":"Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nature Publishing Group; 2011;7(7):416\u201326.","DOI":"10.1038\/nrrheum.2011.68"},{"key":"792_CR15","doi-asserted-by":"crossref","unstructured":"Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nature Publishing Group; 2016;12(5):259\u201368.","DOI":"10.1038\/nrrheum.2015.179"},{"key":"792_CR16","doi-asserted-by":"crossref","unstructured":"O'Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors \u2014 redefining innate immunity. Nature Publishing Group; 2013;13(6):453\u201360.","DOI":"10.1038\/nri3446"},{"issue":"1","key":"792_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2008.11.002","volume":"122","author":"CA Bonjardim","year":"2009","unstructured":"Bonjardim CA, Ferreira PCP, Kroon EG. Interferons: signaling, antiviral and viral evasion. Immunol Lett. 2009;122(1):1\u201311.","journal-title":"Immunol Lett"},{"key":"792_CR18","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol; 2017; 1\u201312. This review gives a detailed background description of interferon signaling and interferonopathies.","DOI":"10.1186\/s12969-016-0094-4"},{"issue":"6121","key":"792_CR19","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121):786\u201391.","journal-title":"Science"},{"key":"792_CR20","unstructured":"Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Annals of the New York Academy of Sciences. 2017. pp. 1\u20138."},{"key":"792_CR21","unstructured":"Tolmie JL, Shillito P, Hughes-Benzie R, Stephenson JBP. The Aicardi-Gouti\u00e8res syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). J Med Genet. 2006;:1\u20134."},{"issue":"06","key":"792_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1055\/s-0036-1592307","volume":"47","author":"J Livingston","year":"2016","unstructured":"\u2022 Livingston J, Crow Y. Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi\u2013Gouti\u00e8res Syndrome and Beyond. Neuropediatrics. 2016;47(06):355\u201360 A thorough descriptor of genotypic and corresponding phenotypic subtypes of AGS.","journal-title":"Neuropediatrics"},{"issue":"9","key":"792_CR23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/ng2082","volume":"39","author":"A Richards","year":"2007","unstructured":"Richards A, van den Maagdenberg AMJM, Jen JC, Kavanagh D, Bertram P, Spitzer D, et al. C-terminal truncations in human 3\u2032-5\u2032 DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Gen. 2007;39(9):1068\u201370.","journal-title":"Nat Gen"},{"issue":"21","key":"792_CR24","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1002\/ajmg.a.32518","volume":"146A","author":"V Navarro","year":"2008","unstructured":"Navarro V, Scott C, Briggs TA, Barete S, Frances C, Lebon P, et al. Two further cases of spondyloenchondrodysplasia (SPENCD) with immune dysregulation. Am J Med Genet A. 2008;146A(21):2810\u20135.","journal-title":"Am J Med Genet A"},{"issue":"6","key":"792_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, et al. Activated STING in a Vascular and Pulmonary Syndrome. N Engl J Med. 2014;371(6):507\u201318.","journal-title":"N Engl J Med"},{"key":"792_CR26","unstructured":"Meuwissen MEC, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer SD, et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J Exp Med. Rockefeller University Press; 2016;213(7):1163\u201374."},{"issue":"1","key":"792_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/BF00972817","volume":"1","author":"EB Singleton","year":"1973","unstructured":"Singleton EB, Merten DF. An unusual syndrome of widened medullary cavities of the metacarpals and phalanges, aortic calcification and abnormal dentition. Pediatr Radiol. 1973;1(1):2\u20137.","journal-title":"Pediatr Radiol"},{"issue":"2","key":"792_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ajhg.2014.12.014","volume":"96","author":"F Rutsch","year":"2015","unstructured":"Rutsch F, MacDougall M, Lu C, Buers I, Mamaeva O, Nitschke Y, et al. A Specific IFIH1 Gain-of-function mutation causes Singleton-Merten Syndrome. Am J Hum Genet. 2015;96(2):275\u201382.","journal-title":"Am J Hum Genet"},{"key":"792_CR29","doi-asserted-by":"crossref","unstructured":"Torrelo A CANDLE syndrome as a paradigm of proteasome-related autoinflammation. Front Immunol 2017;8:489\u20139.","DOI":"10.3389\/fimmu.2017.00927"},{"issue":"1","key":"792_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2016.03.049","volume":"586","author":"WS Lee","year":"2016","unstructured":"Lee WS, Teo KM, Ng RT, Chong SY, Kee BP, Chua KH. Novel mutations in SKIV2L and TTC37 genes in Malaysian children with trichohepatoenteric syndrome. Gene. 2016;586(1):1\u20136.","journal-title":"Gene"},{"key":"792_CR31","doi-asserted-by":"crossref","unstructured":"Pezzani L, Brena M, Callea M, Colombi M, Tadini G. X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature. Am J Med Genet A. Wiley-Blackwell; 2013;161A(6):1414\u201320.","DOI":"10.1002\/ajmg.a.35882"},{"key":"792_CR32","unstructured":"Davidson S, Steiner A, Harapas CR, Masters SL. An update on autoinflammatory diseases: interferonopathies. Curr Rheumatol Rep. Springer US; 2018;20(7):38."},{"key":"792_CR33","doi-asserted-by":"crossref","unstructured":"Fiehn C Familial chilblain lupus - what can we learn from type I interferonopathies? Curr Rheumatol Rep; 2017;:1\u20136.","DOI":"10.1007\/s11926-017-0689-x"},{"issue":"4","key":"792_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00281-015-0500-x","volume":"37","author":"MA Lee-Kirsch","year":"2015","unstructured":"Lee-Kirsch MA, Wolf C, Kretschmer S, Roers A. Type I interferonopathies\u2014an expanding disease spectrum of immunodysregulation. Semin Immunopathol. 2015;37(4):349\u201357.","journal-title":"Semin Immunopathol"},{"key":"792_CR35","first-page":"1243","volume":"374","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology. 2018;374:1243\u20139.","journal-title":"Rheumatology"},{"issue":"5","key":"792_CR36","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.40054","volume":"69","author":"MC Genovese","year":"2017","unstructured":"Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69(5):932\u201342.","journal-title":"Arthritis Rheumatol"},{"key":"792_CR37","unstructured":"Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. Springer International Publishing; 2017;:1\u201315."},{"issue":"25","key":"792_CR38","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386.","journal-title":"N Engl J Med"},{"issue":"6","key":"792_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508\u201319.","journal-title":"N Engl J Med"},{"issue":"16","key":"792_CR40","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350.","journal-title":"N Engl J Med"},{"issue":"16","key":"792_CR41","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525\u201336.","journal-title":"N Engl J Med"},{"key":"792_CR42","doi-asserted-by":"crossref","unstructured":"Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol; 2017;:1\u201310.","DOI":"10.1186\/s12969-017-0212-y"},{"issue":"2","key":"792_CR43","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","volume":"76","author":"N K\u00f6nig","year":"2017","unstructured":"K\u00f6nig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, T\u00fcngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468\u201372.","journal-title":"Ann Rheum Dis"},{"key":"792_CR44","doi-asserted-by":"crossref","unstructured":"Rodero MP, Fr\u00e9mond M-L, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis 2016;75(12):e75\u20135.","DOI":"10.1136\/annrheumdis-2016-210504"},{"key":"792_CR45","doi-asserted-by":"crossref","unstructured":"Seo J, Kang J-A, MD DIS, BS E-BP, MS C-RL, MD SAC, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. Elsevier Ltd; 2017;139(4):1396\u20131399.e12.","DOI":"10.1016\/j.jaci.2016.10.030"},{"key":"792_CR46","unstructured":"Kuriya B, Cohen MD, Keystone E. Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential. Therapeutic Advances in Musculoskeletal. SAGE PublicationsSage UK: London, England; 2017;9(2):37\u201344."},{"key":"792_CR47","unstructured":"Taylor PC, Azeez MA, Kiriakidis S. Filgotinib for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. Taylor & Francis; 2017;00(00):1\u20137."},{"issue":"13","key":"792_CR48","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med"},{"key":"792_CR49","doi-asserted-by":"crossref","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Investig. 2018;:1\u201330.","DOI":"10.1172\/JCI98814"},{"key":"792_CR50","unstructured":"Vincenti F, Tedesco Silva H, Busque S, O\u2019Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. Wiley\/Blackwell (10.1111); 2012;12(9):2446\u201356."},{"issue":"7","key":"792_CR51","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/art.40122","volume":"69","author":"M-L Fr\u00e9mond","year":"2017","unstructured":"Fr\u00e9mond M-L, Uggenti C, Van Eyck L, Melki I, Bondet V, Kitabayashi N, et al. Brief report: blockade of TANK-binding kinase 1\/IKK\u025b inhibits mutant stimulator of interferon genes (STING)-mediated inflammatory responses in human peripheral blood mononuclear cells. Arthritis & Rheumatology. 2017;69(7):1495\u2013501.","journal-title":"Arthritis & Rheumatology"},{"issue":"7","key":"792_CR52","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"792_CR53","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"792_CR54","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837\u201352.","journal-title":"J Rheumatol"},{"issue":"9","key":"792_CR55","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524\u20139.","journal-title":"Ann Rheum Dis"},{"key":"792_CR56","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. Elsevier; 2016;46(3):261\u201371."},{"key":"792_CR57","unstructured":"He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. BioMed Central; 2013;14(1):936."},{"key":"792_CR58","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0792-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T19:28:29Z","timestamp":1573154909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0792-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0792-7","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"8 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"83"}}